Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EM 652

Known as: EM-652 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2003
Highly Cited
2003
OBJECTIVE EM-652 is a pure antiestrogen in human breast and uterine cancer cells that also reduces bone loss and plasma lipid… Expand
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Estrogen receptor (ER)alpha and -beta interact with a variety of coactivator proteins, most notably members of the steroid… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2002
2002
EM‐652 exerts pure antiestrogenic activity in the mammary gland and endometrium, while tamoxifen, the antiestrogen most widely… Expand
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Cardiovascular disease is the leading cause of morbidity and mortality in postmenopausal women. EM-652 (acolbifene) is a fourth… Expand
Is this relevant?
Review
2001
Review
2001
A new understanding of the endocrinology of menopause is that women, at menopause, are not only lacking estrogens resulting from… Expand
Is this relevant?
Review
2001
Review
2001
In order to minimize the risks of endometrial cancer and the development of resistance to antiestrogen therapy, we have… Expand
Is this relevant?
Review
1999
Review
1999
Breast cancer is the most frequent cancer in women while it is the second cause of cancer death. Estrogens are well recognized to… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
A naturally occurring mutation at amino acid 351 (D351Y) in the human estrogen receptor (ER) can change the pharmacology of… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
Highly Cited
1998
Highly Cited
1998
Estrogens act as potent mitogens in a large number of breast cancers, and the use of estrogen receptor (ER) antagonists is… Expand
  • figure 1
  • figure 2
  • figure 5
  • figure 4
  • figure 6
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Although temporary benefits of tamoxifen therapy are observed in up to 40% of women with breast cancer, this compound, which is… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?